Canaccord Genuity Reiterates Buy on Y-mAbs Therapeutics, Maintains $21 Price Target
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst William Plovanic has reiterated a Buy rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and maintained a $21 price target.
June 07, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst reiterates Buy rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and maintains a $21 price target.
The Buy rating reiteration by Canaccord Genuity analyst William Plovanic on Y-mAbs Therapeutics (NASDAQ:YMAB) and maintaining a $21 price target indicates a positive outlook for the stock. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100